Clinical Trial

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma. The main question is: \- Is neoadjuvant treatment with nivolumab and ipilimumab safe and feasible for patientt with high-riks uveal melanoma? In addition pathological response, distant metastases-free survival, overall survival and immunological changes in the tumor microenviroenment after therapy will be assesed.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-02
notable Primary completion pushed: 2029-04-01 -> 2029-06-01 2026-07-02
minor Completion pushed: 2029-04-01 -> 2029-06-01 2026-07-02
Trial Details
NCT Number NCT07501117
Lead Sponsor Inge Marie Svane
Conditions Uveal Melanoma
Enrollment 15 participants
Start Date 2026-06-29
Primary Completion 2029-06-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-01